|
Alexander Y. Rudensky answers a
few questions about this month's fast breaking paper in the field of
Immunology.
From
•>>April 2006
Field:
Immunology
Article Title: A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3
Authors: Fontenot, JD;Rudensky, AY
Journal: NAT IMMUNOL
Volume: 6
Issue: 4
Page: 331-337
Year: APR 2005
* Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA.
* Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA.
* Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98195 USA.
|
Why
do you think your paper is highly cited?
|

“This review paper describes a central role transcription factor Foxp3 plays in development and function of a crucial subset of T cells...”
|
|
This is a review paper in one of the "super-hot"
areas of immunology, and our laboratory has recently made
significant contributions to this field. This particular field
is both of fundamental interest and is also important for
clinically relevant studies.
Does
it describe a new discovery or a new methodology that’s useful
to others?
This review paper describes a central role transcription
factor Foxp3 plays in the development and function of a crucial
subset of T cells—so-called regulatory T cells—controlling
autoimmunity, anti-tumor immunity, and immunity to infections. A
series of studies performed in the laboratory by Jason Fontenot
established a role for Foxp3 as regulatory T cell lineage
specification factor and provided definitive answers to several
outstanding issues in the field.
Most importantly, these studies unequivocally demonstrated
that lack of regulatory T cells results in an early onset,
highly aggressive, and fatal autoimmune pathology affecting
multiple organs.
Could
you summarize the significance of your paper in layman's terms?
This review paper describes a central role transcription
factor Foxp3 plays in development and function of a crucial
subset of T cells controlling autoimmunity, anti-tumor immunity,
and immunity to infections.
How
did you become involved in this research, and were any problems
encountered along the way?
Our interest in regulatory T cell biology can be traced to a
journal club on "historic papers" in immunology
organized by first-year graduate students in the department. A
heated discussion in one of these journal clubs discussing early
work of Sir Peter Medawar*
on neonatal tolerance precipitated our thinking and interest in
the problem of "dominant tolerance".
It also coincided with Marc Gavin joining the lab at that
time as a postdoctoral fellow and Marc was very interested in
starting a new project on regulatory T cells. Another major
event was identification of transcription factor Foxp3 by Fred
Ramsdell and colleagues at the Bothell, Washington-based firm
Celltech, who greatly helped us to jump-start
Foxp3-related research.
The main problem we encountered was the very intense
competition the massive amount of publication in these areas
which resulted in a flood of data of varying quality being
published in a rush.
Alexander Rudensky, Ph.D.
Professor, Department of Immunology, University of Washington
Investigator, Howard Hughes Medical Institute
University of Washington School of Medicine
Seattle, WA, USA
*Sir
Peter Brian Medawar (February 28, 1915—October 2, 1987)
was a Brazilian-born English scientist best known for his work
on how the immune system rejects or accepts organ transplants.
He was co-winner of the 1960 Nobel Prize in Physiology or
Medicine with Sir Frank Macfarlane Burnet.
|
ESI Special Topics,
April 2006
Citing URL - http://www.esi-topics.com/fbp/2006/april06-AlexanderYRudensky.html
|
|